Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.603 USD | -1.89% | +7.03% | +11.87% |
May. 09 | Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000 | MT |
Business Summary
Number of employees: 405
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Zinc Finger Protein
100.0
%
| 111 | 100.0 % | 176 | 100.0 % | +58.34% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 111 | 100.0 % | 176 | 100.0 % | +58.34% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alexander Macrae
CEO | Chief Executive Officer | 61 | 16-05-31 |
Director of Finance/CFO | 46 | 19-02-28 | |
Gregory Davis
CTO | Chief Tech/Sci/R&D Officer | - | 20-04-30 |
Phillip Ramsey
CTO | Chief Tech/Sci/R&D Officer | - | - |
Louise Wilkie
IRC | Investor Relations Contact | - | 20-08-31 |
Amy Pooler
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | 19-08-31 | |
Scott Willoughby
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Peg Horn
BRD | Director/Board Member | 61 | 22-12-14 |
James Meyers
BRD | Director/Board Member | 59 | 19-11-21 |
H. Parker
CHM | Chairman | 68 | 14-06-18 |
Kenneth Hillan
BRD | Director/Board Member | 63 | 20-09-10 |
Robert Carey
BRD | Director/Board Member | 65 | 16-05-31 |
Karen Smith
BRD | Director/Board Member | 56 | 18-06-27 |
Alexander Macrae
CEO | Chief Executive Officer | 61 | 16-05-31 |
John Markels
BRD | Director/Board Member | 58 | 20-02-10 |
Courtney Beers
BRD | Director/Board Member | 54 | 22-12-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 207,510,076 | 190,689,425 ( 91.89 %) | 0 | 91.89 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.12% | 128M | |
+9.58% | 115B | |
+12.41% | 107B | |
-3.52% | 21.6B | |
-12.38% | 22.31B | |
-6.64% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- SGMO Stock
- Company Sangamo Therapeutics, Inc.